ATS 2024: Immunoproteasome Inhibition Reduces Airway Inflammation
Day 2 of allergy-related research at the ATS 2024 conference presented insights into the role of immunoproteasome in treating allergic asthma and the use of electronic noses for monitoring severe asthma.
The American Thoracic Society (ATS) annual conference's Day 2 presentations revealed new findings concerning allergic asthma and its treatment. One study focused on the potential of ONX-0914, an immunoproteasome inhibitor, to reduce type 2 inflammation in airways by regulating the IL-4Ralpha receptor.
Research indicated that inhibiting the immunoproteasome led to increased IL-4Ralpha expression, suggesting its role in dampening inflammation. The study proposed that enhancing immunoproteasome activity could be a promising therapeutic approach for mitigating allergic asthma exacerbations due to its capacity to degrade IL-4Ralpha.
Another presentation discussed the application of electronic noses (eNOSE) in identifying and characterizing treatment responses in severe asthmatics undergoing anti-IL5/5R biologic therapy. While eNOSE technology was used in the U-BIOPRED study to classify asthma, its utility in monitoring treatment responses for severe asthma had not been previously explored.
The PRISM study observed over 12 months that electronic noses could identify at least two distinct disease profiles. One month and six months post-treatment initiation, patients were categorized into four clusters, with responders to therapy being more clearly distinguishable.